Retinitis pigmentosa is a heritable group of blinding diseases resulting from loss of photoreceptors, primarily rods and secondarily cones, that mediate central vision. Loss of retinal vasculature is a presumed metabolic consequence of photoreceptor degeneration. A new study shows that autologous bone marrow–derived lineage-negative hematopoietic stem cells, which incorporate into the degenerating blood vessels in two murine models of retinitis pigmentosa, rd1 and rd10, prevent cone loss (see the related article beginning on page 763). The use of autologous bone marrow might avoid problems with rejection while preserving central cone vision in a wide variety of genetically disparate retinal degenerative diseases.

Potential therapies for retinitis pigmentosa

Encouraging advances in gene therapy have led to partial reversal of the phenotypic changes observed in some animal models of retinitis pigmentosa, the rd (3) and rds (4) mouse, the Royal College of Surgeons rat (5) and in the RPE65 pheno-type in dogs (6), after viral transfection of photoreceptors or retinal pigment epithelium with the appropriate wild-type gene (7, 8). However, specific genetic defects have been found in a relatively small number of retinal degenerative diseases, which thereby limits the potential application of gene therapy for those few patients with a known mutation. The use of trophic factors (9–11) and calcium channel blockers (12) has slowed disease progression in some retinal degeneration models, but in the case of trophic factor treatment, delivery of high-molecular-weight proteins to the retina has presented challenging problems. The use of cells expressing a single transgene encoding a neurotrophic substance (ciliary neurotrophic factor), encapsulated to prevent induction of an immune response, has recently been studied in the clinic, although encapsulated cells still retain the potential for rejection (11). There has been some success with transplantation of neural stem cells, but this approach is limited by political and ethical controversies related to the use of embryonic stem cells, as well as by cell rejection (13).

An attractive therapeutic intervention, short of correcting every individual gene mutation, would be one that affords a generic neuroprotective effect with minimal intravitreal injections and without risk of rejection. Protection of both rods and cones would be optimal, but protection of cones alone would be very beneficial, since the human retina is cone-dominated; these cells, responsible for fine and color vision, are concentrated in the central retina (macula), and if they could be maintained, most patients would have highly functional vision, even in the absence of rods.

Autologous bone marrow–derived stem cells prevent loss of cones

In this issue of the JCI, Otani and coworkers (14) have explored a novel and widely applicable approach to the treatment of these diseases that may offer cone neuroprotection without immune rejection. This work is based on the prior observations of this group and others showing that adult bone marrow–derived lineage-negative hematopoietic stem cells (Lin–HSCs) containing endothelial precursors incorporate into degenerating (or newly forming) vessels and stabilize and rescue retinal blood vessels that would ordinarily completely disappear secondary to photoreceptor cell loss (15–17). In their current study, this group has shown that stabilization of the vasculature with Lin–HSCs, which integrate into and associate with degenerating vessels, can prevent loss of cones in 2 mouse models of retinal degeneration, rd1 and rd10 (14) (Figure 1). This effect was observed following delivery of bone marrow derived from genetically defective mice as well as bone marrow derived from wild-type mice. This observation in mice suggests that in humans, the patient’s own bone marrow cells (even from patients with a genetic defect) might provide an efficacious cone neuroprotective effect. This effect might not only preserve central vision but might circumvent many of the unwanted potential side effects associated with the use of viral vectors in long-term gene therapy as well as avoiding the problem of rejection that may result following administration of embryonic stem cells.

Can this mouse study be applied to patients?

There are many questions and much work that lies between the current study and clinical application; what is the specific

Nonstandard abbreviations used: Lin– HSC, lineage-negative hematopoietic stem cell.

Conflict of interest: The author has declared that no conflict of interest exists.


Department of Ophthalmology, Children’s Hospital, Boston, Massachusetts, USA.

Lois E.H. Smith

Bone marrow–derived stem cells preserve cone vision in retinitis pigmentosa
The current study (14) uses a cell-based therapeutic approach based on trophic effects of the natural products of the cells themselves. Using ex vivo transfection with plasmids encoding other trophic substances, it may be possible to achieve an even greater rescue effect (10).

Although the results reported in the study by Otani et al. in this issue (14) suggest a potentially useful approach to preventing cone loss, there are some limitations. This work does not address the issue of rod loss. Nor is the approach useful for diseases that affect cones directly. Those photoreceptors that have already degenerated will not be rescued, and many patients come to the attention of the ophthalmologist late in the disease course. Nor is this paradigm likely to work for patients very early in the course of disease prior to the loss of vessels, since stem cells require a template for engraftment, which is uncovered only after vessels degenerate. Perhaps for those patients, selective ablation of vessels with photodynamic therapy would provide the basis for engraftment of endothelial cell precursors.

Although this study raises many interesting questions, including the question of the precise relationship between retinal neuronal and vascular degeneration, it is not necessary to answer all of them before proceeding further with this new approach to preventing cone loss in retinitis pigmentosa.

Address correspondence to: Lois E.H. Smith, Department of Ophthalmology, Fegan 4, Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Phone: (617) 919-2529; Fax: (617) 730-0392; E-mail: lois.smith@childrens.harvard.edu.
Prostanoids and blood pressure: which way is up?

Helene Francois and Thomas M. Coffman

Division of Nephrology, Department of Medicine, Duke University and Durham Veterans Affairs Medical Center, Durham, North Carolina, USA.

Members of the family of prostanoids, made up of prostaglandins and thromboxanes, are generated via COX-mediated metabolism of arachidonic acid. These lipid mediators exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion. As COX inhibition is often associated with sodium retention leading to edema and hypertension, prostanoids appear to have a role in preventing the development of high blood pressure. On the other hand, prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) and PGI\textsubscript{2} have also been implicated as determinants of renin secretion. A new study suggests that PGI\textsubscript{2} plays a critical role in stimulating renin release and promoting hypertension following renal artery stenosis (see the related article beginning on page 805).

Prostanoids are generated by COX-mediated metabolism of arachidonic acid. These lipid mediators have a myriad of biological actions (1, 2). A role for prostanoids in the regulation of blood pressure was originally suggested by early observations that prostaglandins and thromboxanes affect vascular tone and renal excretory functions (3). Later, the impact of prostanoids upon blood pressure in humans was clearly demonstrated through clinical experiences with NSAIDs. NSAIDs, among the most widely prescribed drugs worldwide, act by inhibiting COX enzymes and hence blocking prostaglandin production. Sodium retention leading to edema and hypertension is often observed in patients treated with NSAIDs (4, 5). However, increased blood pressure after treatment with NSAIDs is observed primarily in patients with pre-existing hypertension (6–8), suggesting a compensatory role for the prostanoïd system in attenuating or preventing the development of high blood pressure.

Data from clinical trials suggest that nonselective NSAIDs, which inhibit both COX isomers (COX-1 and -2), and selective COX-2 inhibitors (9–12) have similar propensities to cause hypertension. The theory that COX-2-dependent prostanoids resist the development of hypertension is further supported by experiments showing that COX-2 inhibitors or the genetic absence of COX-2 markedly augment the vasoconstrictor actions of Ang II (13). Among the prostanoids, prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) and PGI\textsubscript{2} are potent vasodilators that provide functional hemangioblast activity during retinal neovascularization. In this regard, studies in humans suggest that COX-2 may be specifically linked to the generation of PGI\textsubscript{2} in the systemic circulation (14). The predominant inhibition of PGI\textsubscript{2} by COX-2 inhibitors has been posited as an explanation for putative associations between COX-2 inhibitors and the development of cardiovascular complications (15), including hypertension (16, 17).

Prostanoids and renovascular hypertension

In this issue of the JCI, Fujino and associates show that the absence of the receptor for PGI\textsubscript{2} (the I-prostanoid [IP] receptor) confers substantial resistance to the development of renovascular hypertension (18). Based on the discussion above, these findings may seem surprising.